Idian Tablet 10 mg (Empagliflozin)
Empagliflozin 10mg
Tablet · Prescription medication
IlYang Pharmaceutical Co., Ltd.
MFDS item code 202102070 · Approved 2021.03.05
Improvement of glycemic control in adults with type 2 diabetes mellitus
This medicine is an adjunct treatment to help adults with type 2 diabetes more effectively control their blood sugar when used in combination with diet and exercise. It can be used as monotherapy, and in cases where blood sugar control is difficult, it can be combined with metformin, pioglitazone, sulfonylureas, insulin, or DPP-4 inhibitors. Particularly, it is important for patients with type 2 diabetes who have cardiovascular diseases to consult with professionals due to the risk of cardiovascular events. This drug improves blood sugar control in patients and aids in diabetes management.
The recommended dose of this medicine is 10 mg once daily for monotherapy and as add-on combination therapy with other glucose-lowering agents, such as insulin. If 10 mg of this medicine is well tolerated but additional glycemic control is needed, the dose may be increased to 25 mg once daily. When this medicine is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, 3. Adverse Reactions). This medicine may be taken with or without food. Swallow the tablet whole. If you miss a dose, take it as soon as you remember. Do not take a double dose in one day. Special populations •Patients with renal impairment No dose adjustment is required for patients with mild renal impairment. Treatment with this medicine should not be initiated in patients with an estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73m2 [or CrCl < 60 ml/min]. In patients who tolerate this medicine well but have a persistent glomerular filtration rate < 60ml/min/1.73m2 [or CrCl < 60 ml/min], the dose should be adjusted to or maintained at 10 mg once daily. This medicine should be discontinued if the glomerular filtration rate decreases to < 45 ml/min/1.73m2 [or CrCl < 45 ml/min]. Do not use this medicine in patients with end-stage renal disease (ESRD) or those on dialysis, as efficacy is not expected. •Patients with hepatic impairment No dose adjustment is required for patients with mild or moderate hepatic impairment. Use of this medicine is not recommended in patients with severe hepatic impairment, as it has not been studied in this population. •Elderly patients No dose adjustment is required based on age. Renal function and the risk of volume depletion should be considered in patients 75 years of age and older. Initiation of this medicine is not recommended in patients 85 years of age and older because clinical experience is limited (see Precautions for Use, 4. General Precautions).
This medicine should not be administered to certain patients. First, patients with allergic reactions to the active ingredient or any components of this medicine should not use it. Second, this drug is not given to patients with type 1 diabetes or diabetic ketoacidosis. Third, patients with severely impaired renal function, specifically those with a glomerular filtration rate below 30 mL/min/1.73m², end-stage renal disease, or those undergoing dialysis should not use this medicine. Fourth, because it contains lactose, it should not be administered to patients with genetic issues like galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption. This medicine should be used cautiously in patients with reduced renal function. Especially, patients with a glomerular filtration rate below 60 mL/min/1.73m² are recommended not to start this medicine initially, and even for those who tolerate the medicine well, dosage adjustments should be made if the filtration rate drops below 60, and it should be discontinued if it falls below 45. This medicine is not effective for patients with end-stage renal disease or those undergoing dialysis. For patients with mild to moderate heart failure, this medicine should be used cautiously, and it is not recommended for severe heart failure patients. Additionally, when used with insulin or sulfonylureas, the risk of hypoglycemia may occur, therefore the dosages of these medications may need to be reduced. During the use of this medicine, various adverse reactions may occur. The most common adverse reaction is hypoglycemia, which can occur when used in combination with insulin or sulfonylureas. Other reported problems include genital infections or urinary tract infections, increased urination, skin rash, itching, low blood pressure, dehydration, etc. Serious adverse reactions include ketoacidosis, urosepsis, pyelonephritis, and perineal necrosis (severe skin and tissue infection), so if these symptoms occur, immediate consultation with healthcare professionals is necessary. Elderly patients, particularly those over 75 years old, should take caution due to the high risk of fluid loss, and there is limited clinical experience in those over 85 years old. This medicine affects blood sugar control, so care must be taken when interpreting blood sugar test results, and accurate blood sugar control status cannot be determined with the 1,5-AG test. The use of this medicine during pregnancy is not recommended, and it should be discontinued if pregnancy is confirmed. During breastfeeding, as this drug may be excreted in breast milk, it is advisable to stop breastfeeding. For children under 18 years of age, safety and efficacy have not been established, so it is not used. No special toxicity has been reported in cases of overdose, but appropriate treatment according to clinical conditions is necessary. This medicine should be kept out of the reach of children, and care should be taken when transferring it to another container as it may affect the quality. This medicine may cause blood pressure lowering and fluid loss, so careful monitoring of the physical condition is necessary when administered to patients with cardiovascular diseases or hypotension, especially the elderly. There is a risk of hypoglycemia when driving or operating machinery, especially in patients taking insulin or sulfonylureas, so caution is essential. There may be potential interactions with other medications being taken simultaneously, so healthcare professionals should be notified of any other medications being used. During the use of this medicine, regular kidney function tests should be conducted, and immediate consultation with healthcare professionals should occur if any unusual symptoms appear.
Not everyone experiences these, and they can vary from person to person.
This medicine may be sensitive to air or moisture, so it must be stored in a sealed container. It is best to keep the storage temperature between 1 degree and 30 degrees Celsius at room temperature. By storing it this way, the efficacy of the medicine can be maintained for a longer period.
Pale yellow, round, biconvex film-coated tablets
10 tablets/box [10 tablets/PTP x 1], 30 tablets/box [10 tablets/PTP x 3], 30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Empagliflozin 10mg
Tablet · Prescription medication
IlYang Pharmaceutical Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Boehringer Ingelheim Korea Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Boehringer Ingelheim Korea Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Donggu Bio Pharmaceutical Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Dong Gu Bio Pharmaceutical Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Korea Prime Pharmaceuticals Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Korea Prime Pharmaceutical Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Kips Biopharma Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.